ASSESSMENT OF THE QUALITY OF LIFE OF PATIENTS WITH THE JUVENILE IDIOPATHIC ARTHRITIS TREATED BY THE ETANERCEPT
https://doi.org/10.15690/vsp.v13i4.1081
Abstract
Aim: To assess the influence of the genetically engineered biologic drug etanercept on the quality of life of patients with juvenile idiopathic arthritis (JIA). Patients and methods: The research included 85 children with poly-and oligoarticular variant of the JIA at the age of 5 (2; 17) years. The assessment of the quality of life of patients was carried out by means of the parental version of a special questionnaire
CHAQ (Childhood Health Assessment Questionnaire), Health Utilities Index Mark 3 (HUI3) questionnaire. The doctor and parents of the patient also assessed the global activity of the illness by the 100-mm visual analog scale (VAS) before the etanercept prescription and in 1, 6 and 12 months. All patients before the etanercept prescription received immunodepressants. Results: Fast dynamics of the increase of an average point of the quality of life (the response in 1 month after the therapy beginning) was noted by the attributes of a questionnaire of HUI3 «emotions» — from 0.82 (± 0.18) to 0.90 (± 0.13), p =0.001, «cognitive abilities» — from 0.85 (± 0.17) to 0.91 (± 0.18), p =0.006, and «pain» — from 0.78 (± 0.23) to 0.91 (± 0.1), p < 0.001. In 12 months of the treatment the average point of the quality of life raised also by such attributes as «locomotivity» — from 0.85 (± 0.3) to 0.99 (± 0.06), p < 0.0001, and «fine motor skills» — from 0.9 (± 0.19) to 0.98 (± 0.05), p < 0.001. Conclusion: Treatment with the etanercept provided the improvement of the quality of life of children with the JIA and their families, improvement of physical activity and emotional state of patients.
Key words: children, juvenile idiopathic arthritis, etanercept, quality of life, Health Utilities Index Mark 3.
CHAQ (Childhood Health Assessment Questionnaire), Health Utilities Index Mark 3 (HUI3) questionnaire. The doctor and parents of the patient also assessed the global activity of the illness by the 100-mm visual analog scale (VAS) before the etanercept prescription and in 1, 6 and 12 months. All patients before the etanercept prescription received immunodepressants. Results: Fast dynamics of the increase of an average point of the quality of life (the response in 1 month after the therapy beginning) was noted by the attributes of a questionnaire of HUI3 «emotions» — from 0.82 (± 0.18) to 0.90 (± 0.13), p =0.001, «cognitive abilities» — from 0.85 (± 0.17) to 0.91 (± 0.18), p =0.006, and «pain» — from 0.78 (± 0.23) to 0.91 (± 0.1), p < 0.001. In 12 months of the treatment the average point of the quality of life raised also by such attributes as «locomotivity» — from 0.85 (± 0.3) to 0.99 (± 0.06), p < 0.0001, and «fine motor skills» — from 0.9 (± 0.19) to 0.98 (± 0.05), p < 0.001. Conclusion: Treatment with the etanercept provided the improvement of the quality of life of children with the JIA and their families, improvement of physical activity and emotional state of patients.
Key words: children, juvenile idiopathic arthritis, etanercept, quality of life, Health Utilities Index Mark 3.
Keywords
Supporting agencies: Pharmaceutical companies: Roche, Pfizer, Bristol-Myers Squibb, Centocor, Novartis..
About the Authors
A. N. Fetisova
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
E. I. Alexeeva
Scientific Centre of Children Health, Moscow
I.M. Sechenov First Moscow State Medical University
Russian Federation
Alexeeva Ekaterina Iosifovna, PhD, professor, Head of the Pediatric Faculty of I. M. Sechenov First MSMU, Head of the Rheumatologic Department of SCCH
Russian Federation
Alexeeva Ekaterina Iosifovna, PhD, professor, Head of the Pediatric Faculty of I. M. Sechenov First MSMU, Head of the Rheumatologic Department of SCCH
T. M. Bzarova
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
S. I. Valieva
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
V. V. Chernikov
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
I. V. Vinyarskaya
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
R. V. Denisova
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
K. B. Isaeva
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
E. G. Chistyakova
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
Т. V. Sleptsova
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
N. I. Taibulatov
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
References
1. Cassidy J. T., Petty R. E., Laxer R. M., Lindsley C. B. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier. 2011; 794 p.
2. Alexeeva E. I. Revmaticheskie bolezni i ikh vliyanie na kachestvo zhizni detei i ikh semei. Kachestvo zhizni [Rheumatic Diseases and the Infuence on the Quality of Life of Children and their Families. Quality of Life.]. Moscow, Meditsina, 2008. pp. 14–17.
3. Baranov A. A. Pediatriya. Klinicheskie rekomendatsii [Pediatrics. Clinical Recommendations]. Moscow, GEOTAR-Media, 2009. pp. 387–420.
4. Huygen A. C., Kuis W., Sinnema G. Psychological, behavioral and social adjustment in children and adolescents with juvenile chronic arthritis. Ann. Rheum. Dis. 2000; 59 (4): 276–282.
5. Berard R. A., Laxer R. M. Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis. 2013; 13 (11): 1623–1630. Doi: 10.1517/14712598.2013.840580.
6. Al’bitskii V.Yu., Vinyarskaya I. V., Chernikov V. V., Malygina L. V. RPZh — Russian pediatric journal. 2011; 5: 45–49.
7. Prince F. H., Geerdink L. M., Borsboom G. J., Twilt M., van Rossum M. A., Hoppenreijs E. P., Cate R. T., Koopman-Keemink Y., van Santen-Hoeufft M., Raat H., van Suijlekom-Smit L. W. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthriti. Downloaded from ard.bmj.com on April 14, 2014. Published by group.bmj.com
8. Giannini E. H., Ilowite N. T., Lovell D. J. Wallace C. A., Rabinovich C. E., Reiff A. et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009; 60 (9): 2794–2804.
9. Bzarova T. M., Alekseeva E. I., Fetisova A. N., Tsurikova N. A., Valieva S. I., Denisova R. V., Mitenko E. V., Sleptsova T. V., Isaeva K. B., Chistyakova E. G., Taibulatov N. I., Ryazanov M. V., Anikin A. V., Zelikovich E. I., Kurilenkov G. V., Semikina E. L. Vopr. sovr. pediatrii — Current pediatrics. 2012; 11 (4): 29–37.
10. Feeny D., Furlong W., Torrance G. W., Goldsmith C. H., Zhu Z., DePauw S., Denton M., Boyle M. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med. Care. 2002; 40 (2): 113–128.
11. Torrance G. W., Furlong W., Feeny D., Boyle M. H. Multi- attribute preference functions. Health Utilities Index. PharmacoEconomics. 1995; 7 (6): 503–520.
12. Strand V., Singh J. A. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from rando mized controlled trials. Am. J. Manag. Care. 2008; 14 (4): 234–254. 13. Nasonov E. L. Ter. arkhiv — Therapeutic archive. 2007; 5: 5–8.
13. Minden K., Niewerth M., Listing J., Biedermann T., Bollow M., Schontube M., Zink A. Long-term outcome in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2002; 46: 2392–2401.
14. Nikishina I. P. RMZh — Russian medical journal. 2010; 18 (27): 2–7.
15. Prince F. H. M., Twilt M., ten Cate R., van Rossum M. A., Armbrust W., Hoppenreijs E. P., van Santen-Hoeufft M., KoopmanKeemink Y., Wulffraat N. M., van Suijlekom-Smit L. W. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann. Rheum. Dis. Published online 15 Apr 2008. Doi: 10.1136/ard.2007.087411
16. Hayward K., Wallace C. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res. Ther. 2009; 11: 216. Doi: 10.1186/ar2619.
17. Breda L., Del Torto M., De Sanctis S., Chiarelli F. Biologics in children’s autoimmune disorders: efficacy and safety. Eur. J. Pediatr. Doi: 10.1007/s00431-010-1238-z.
18. Pain C., McCann L. Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics: Targets & Therapy. 2009; 3: 127–139.
19. Nikishina I. P. RMZh — Russian medical journal. 2010; 18 (27): 2–7.
20. Alexeeva E. I., Bzarova T. M., Tsurikova N. A., Denisova R. V. Vopr. sovr. pediatrii — Current pediatrics. 2011; 10 (6): 26–34.
Review
For citations:
Fetisova A.N., Alexeeva E.I., Bzarova T.M., Valieva S.I., Chernikov V.V., Vinyarskaya I.V., Denisova R.V., Isaeva K.B., Chistyakova E.G., Sleptsova Т.V., Taibulatov N.I. ASSESSMENT OF THE QUALITY OF LIFE OF PATIENTS WITH THE JUVENILE IDIOPATHIC ARTHRITIS TREATED BY THE ETANERCEPT. Current Pediatrics. 2014;13(4):26-32. (In Russ.) https://doi.org/10.15690/vsp.v13i4.1081
Views:
861
Email this article 
